Cover Image
Market Research Report
Product code
972354

Global Anticoagulants Market Forecast 2021-2028

Published: | Inkwood Research | 210 Pages | Delivery time: 2-3 business days

Price

Back to Top
Global Anticoagulants Market Forecast 2021-2028
Published: November 24, 2020
Inkwood Research
Content info: 210 Pages
Delivery time: 2-3 business days
  • ALL
  • Description
  • Table of Contents
Description

KEY FINDINGS

The global anticoagulants market is estimated to project a CAGR of 8.42% during the forecast period of 2021 to 2028. The key market growth drivers include, the surging approval of novel oral anticoagulants (NOAC), technical advancements, and the surging incidence of chronic diseases.

MARKET INSIGHTS

Anticoagulants or blood thinners, entail chemical substances that minimize or prevent blood coagulation, thereby prolonging the clotting period. Typically, a blood clot is a seal created by the blood to stop bleeding from wounds, and anticoagulants are medicines that aid the prevention of blood clots. They are prescribed to patients with a high risk of forming clots, in order to reduce the chances of developing critical ailments, such as heart attacks and strokes.

Chronic conditions like atrial fibrillation, pulmonary embolism, neurological ailments, deep vein thrombosis, and the rising number of surgical procedures cause complications such as, blood clotting, nose bleeds, menorrhagia, and bruising during surgery. Besides, the most common chronic diseases result in clinical blood clotting, including inherited deficiencies. As per the World Health Organization (WHO), chronic diseases have continued to remain a mostly global issue, accounting for nearly 60% of all fatalities, across the world. Therefore, the rising incidence of chronic diseases has resulted in the increased use of coagulants for treating them.

REGIONAL INSIGHTS

The global anticoagulants market growth is assessed by analyzing the Asia Pacific, North America, Europe, and the rest of the world. North America is anticipated to harbor the largest revenue share during the forecast period, primarily owing to the high awareness regarding novel therapeutics among patients as well as health care professionals, and the easy availability of treatments. Additionally, the easy disease diagnosis, the strong presence of hospitals and diagnostic centers, and the massive target population also play a crucial role in augmenting the market growth.

COMPETITIVE INSIGHTS

The industrial rivalry is anticipated to be high among key players, especially in the process of developing new drugs. The global anticoagulant market's pipeline products are also gradually increasing among significant biopharmaceutical enterprises, across several major nations.

Some of the leading enterprises operating in the market include, Bayer AG, Daiichi Sankyo, Abbott Laboratories, Pfizer Inc, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Table of Contents
Product Code: 34919

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. KEY DRIVERS
    • 3.1.1. SURGING PREVALENCE OF CHRONIC DISEASE
    • 3.1.2. ADVANCEMENTS IN TECHNOLOGY
    • 3.1.3. RISING APPROVAL OF NOVEL ORAL ANTICOAGULANTS (NOACS)
  • 3.2. KEY RESTRAINTS
    • 3.2.1. SIDE EFFECTS ASSOCIATED WITH ANTICOAGULANTS TREATMENT
    • 3.2.2. HIGH PRICE OF NOACS
    • 3.2.3. STRINGENT GOVERNMENT REGULATIONS

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCES ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRY
    • 4.1.2. THREAT OF SUBSTITUTION
    • 4.1.3. BUYER'S POWER
    • 4.1.4. SUPPLIER'S POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. IMPACT OF COVID-19 ON ANTICOAGULANTS MARKET
  • 4.3. OPPORTUNITY MATRIX
  • 4.4. VENDOR LANDSCAPE
  • 4.5. KEY INVESTMENT INSIGHTS

5. MARKET BY APPLICATION

  • 5.1. ATRIAL FIBRILLATION & HEART ATTACK
  • 5.2. PULMONARY EMBOLISM (PE)
  • 5.3. DEEP VEIN THROMBOSIS (DVT)
  • 5.4. STROKE
  • 5.5. OTHER APPLICATIONS

6. MARKET BY ROUTE OF ADMINISTRATION

  • 6.1. ORAL ANTICOAGULANTS
  • 6.2. INJECTABLE ANTICOAGULANTS

7. MARKET BY DRUG CLASS

  • 7.1. NOACS
    • 7.1.1. XARELTO
    • 7.1.2. ELIQUIS
    • 7.1.3. PRADAXA
    • 7.1.4. SAVAYSA & LIXIANA
    • 7.1.5. BEVYXXA
  • 7.2. HEPARINS & LOW-MOLECULAR-WEIGHT HEPARINS (LMWHS)
  • 7.3. VITAMIN K ANTAGONISTS
  • 7.4. OTHER DRUG CLASS

8. GEOGRAPHICAL ANALYSIS

  • 8.1. NORTH AMERICA
    • 8.1.1. MARKET SIZE & ESTIMATES
    • 8.1.2. KEY GROWTH ENABLERS
    • 8.1.3. KEY CHALLENGES
    • 8.1.4. KEY PLAYERS
    • 8.1.5. COUNTRY ANALYSIS
      • 8.1.5.1. UNITED STATES
      • 8.1.5.2. CANADA
  • 8.2. EUROPE
    • 8.2.1. MARKET SIZE & ESTIMATES
    • 8.2.2. KEY GROWTH ENABLERS
    • 8.2.3. KEY CHALLENGES
    • 8.2.4. KEY PLAYERS
    • 8.2.5. COUNTRY ANALYSIS
      • 8.2.5.1. GERMANY
      • 8.2.5.2. FRANCE
      • 8.2.5.3. UNITED KINGDOM
      • 8.2.5.4. ITALY
      • 8.2.5.5. RUSSIA
      • 8.2.5.6. BELGIUM
      • 8.2.5.7. POLAND
      • 8.2.5.8. REST OF EUROPE
  • 8.3. ASIA PACIFIC
    • 8.3.1. MARKET SIZE & ESTIMATES
    • 8.3.2. KEY GROWTH ENABLERS
    • 8.3.3. KEY CHALLENGES
    • 8.3.4. KEY PLAYERS
    • 8.3.5. COUNTRY ANALYSIS
      • 8.3.5.1. CHINA
      • 8.3.5.2. JAPAN
      • 8.3.5.3. AUSTRALIA & NEW ZEALAND
      • 8.3.5.4. INDIA
      • 8.3.5.5. SOUTH KOREA
      • 8.3.5.6. THAILAND
      • 8.3.5.7. INDONESIA
      • 8.3.5.8. VIETNAM
      • 8.3.5.9. REST OF ASIA PACIFIC
  • 8.4. REST OF WORLD
    • 8.4.1. MARKET SIZE & ESTIMATES
    • 8.4.2. KEY GROWTH ENABLERS
    • 8.4.3. KEY CHALLENGE
    • 8.4.4. KEY PLAYERS
    • 8.4.5. REGIONAL ANALYSIS
      • 8.4.5.1. LATIN AMERICA
      • 8.4.5.2. MIDDLE EAST & AFRICA

9. COMPETITIVE LANDSCAPE

  • 9.1. KEY STRATEGIC DEVELOPMENTS
    • 9.1.1. MERGER & ACQUISITIONS
    • 9.1.2. PRODUCT LAUNCH & DEVELOPMENTS
    • 9.1.3. PARTNERSHIP, CONTRACT/ AGREEMENT & COLLABORATION
    • 9.1.4. BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
  • 9.2. COMPANY PROFILE
    • 9.2.1. ABBOTT LABORATORIES
    • 9.2.2. ALEXION PHARMACEUTICAL INC
    • 9.2.3. ASPEN PHARMACARE HOLDINGS LIMITED
    • 9.2.4. BAYER AG
    • 9.2.5. BOEHRINGER INGELHEIM GMBH
    • 9.2.6. BRISTOL-MYERS SQUIBB COMPANY
    • 9.2.7. DAIICHI SANKYO
    • 9.2.8. DR. REDDY'S LABORATORIES
    • 9.2.9. GLAXOSMITHKLINE PLC
    • 9.2.10. JOHNSON & JOHNSON
    • 9.2.11. LEO PHARMA AS
    • 9.2.12. MERCK & CO
    • 9.2.13. NOVARTIS AG
    • 9.2.14. PFIZER INC
    • 9.2.15. SANOFI

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - ANTICOAGULANTS
  • TABLE 2: GLOBAL ANTICOAGULANTS MARKET, BY APPLICATION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 3: GLOBAL ANTICOAGULANTS MARKET, BY APPLICATION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 4: GLOBAL ATRIAL FIBRILLATION & HEART ATTACK MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 5: GLOBAL ATRIAL FIBRILLATION & HEART ATTACK MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 6: GLOBAL PULMONARY EMBOLISM (PE) MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 7: GLOBAL PULMONARY EMBOLISM (PE) MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 8: GLOBAL DEEP VEIN THROMBOSIS (DVT) MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 9: GLOBAL DEEP VEIN THROMBOSIS (DVT) MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 10: GLOBAL STROKE MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 11: GLOBAL STROKE MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 12: GLOBAL OTHER APPLICATIONS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 13: GLOBAL OTHER APPLICATIONS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 14: GLOBAL ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 15: GLOBAL ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 16: GLOBAL ORAL ANTICOAGULANTS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 17: GLOBAL ORAL ANTICOAGULANTS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 18: GLOBAL INJECTABLE ANTICOAGULANTS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 19: GLOBAL INJECTABLE ANTICOAGULANTS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 20: GLOBAL ANTICOAGULANTS MARKET, BY DRUG CLASS, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 21: GLOBAL ANTICOAGULANTS MARKET, BY DRUG CLASS, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 22: GLOBAL NOACS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 23: GLOBAL NOACS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 24: GLOBAL NOACS MARKET, BY TYPE, FORECAST YEARS, 2018-2021, (IN $ MILLION)
  • TABLE 25: GLOBAL HEPARINS & LMWH MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 26: GLOBAL HEPARINS & LMWH MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 27: GLOBAL VITAMIN K ANTAGONISTS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 28: GLOBAL VITAMIN K ANTAGONISTS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 29: GLOBAL OTHER DRUG CLASS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 30: GLOBAL OTHER DRUG CLASS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 31: GLOBAL ANTICOAGULANTS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 32: GLOBAL ANTICOAGULANTS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 33: NORTH AMERICA ANTICOAGULANTS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 34: NORTH AMERICA ANTICOAGULANTS MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 35: LEADING PLAYERS OPERATING IN NORTH AMERICA ANTICOAGULANTS MARKET
  • TABLE 36: EUROPE ANTICOAGULANTS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 37: EUROPE ANTICOAGULANTS MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 38: LEADING PLAYERS OPERATING IN EUROPE ANTICOAGULANTS MARKET
  • TABLE 39: ASIA PACIFIC ANTICOAGULANTS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 40: ASIA PACIFIC ANTICOAGULANTS MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 41: LEADING PLAYERS OPERATING IN ASIA PACIFIC ANTICOAGULANTS MARKET
  • TABLE 42: REST OF WORLD ANTICOAGULANTS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 43: REST OF WORLD ANTICOAGULANTS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 44: LEADING PLAYERS OPERATING IN REST OF WORLD ANTICOAGULANTS MARKET

LIST OF FIGURES

  • FIGURE 1: CHRONIC CONDITIONS IN PATIENTS HOSPITALIZED WITH COVID-19 IN THE UNITED STATES
  • FIGURE 2: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 3: OPPORTUNITY MATRIX
  • FIGURE 4: VENDOR LANDSCAPE
  • FIGURE 5: KEY INVESTMENT INSIGHTS
  • FIGURE 6: GLOBAL ANTICOAGULANTS MARKET, BY APPLICATION, IN 2020
  • FIGURE 7: GLOBAL ANTICOAGULANTS MARKET, BY ATRIAL FIBRILLATION & HEART ATTACK, 2021-2028 (IN $ MILLION)
  • FIGURE 8: GLOBAL ANTICOAGULANTS MARKET, BY PULMONARY EMBOLISM (PE), 2021-2028 (IN $ MILLION)
  • FIGURE 9: GLOBAL ANTICOAGULANTS MARKET, BY DEEP VEIN THROMBOSIS (DVT), 2021-2028 (IN $ MILLION)
  • FIGURE 10: GLOBAL ANTICOAGULANTS MARKET, BY STROKE, 2021-2028 (IN $ MILLION)
  • FIGURE 11: GLOBAL ANTICOAGULANTS MARKET, BY OTHER APPLICATIONS, 2021-2028 (IN $ MILLION)
  • FIGURE 12: GLOBAL ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, IN 2020
  • FIGURE 13: GLOBAL ANTICOAGULANTS MARKET, BY ORAL ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 14: GLOBAL ANTICOAGULANTS MARKET, BY INJECTABLE ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 15: GLOBAL ANTICOAGULANTS MARKET, BY DRUG CLASS, IN 2020
  • FIGURE 16: GLOBAL ANTICOAGULANTS MARKET, BY NOACS, 2021-2028 (IN $ MILLION)
  • FIGURE 17: GLOBAL NOACS MARKET, BY XARELTO, 2018-2021 (IN $ MILLION)
  • FIGURE 18: GLOBAL NOACS MARKET, BY ELIQUIS, 2021-2021 (IN $ MILLION)
  • FIGURE 19: GLOBAL NOACS MARKET, BY PRADAXA, 2021-2021 (IN $ MILLION)
  • FIGURE 20: GLOBAL NOACS MARKET, BY SAVAYSA & LIXIANA, 2021-2021 (IN $ MILLION)
  • FIGURE 21: GLOBAL NOACS MARKET, BY BEVYXXA, 2021-2021 (IN $ MILLION)
  • FIGURE 22: GLOBAL ANTICOAGULANTS MARKET, BY HEPARINS & LOW-MOLECULAR-WEIGHT HEPARINS (LMWHS), 2021-2028 (IN $ MILLION)
  • FIGURE 23: GLOBAL ANTICOAGULANTS MARKET, BY VITAMIN K ANTAGONISTS, 2021-2028 (IN $ MILLION)
  • FIGURE 24: GLOBAL ANTICOAGULANTS MARKET, BY OTHER DRUG CLASS, 2021-2028 (IN $ MILLION)
  • FIGURE 25: NORTH AMERICA ANTICOAGULANTS MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 26: UNITED STATES ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 27: CANADA ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 28: EUROPE ANTICOAGULANTS MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 29: GERMANY ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 30: FRANCE ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 31: UNITED KINGDOM ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 32: ITALY ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 33: RUSSIA ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 34: BELGIUM ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 35: POLAND ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 36: REST OF EUROPE ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 37: ASIA PACIFIC ANTICOAGULANTS MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 38: CHINA ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 39: JAPAN ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 40: AUSTRALIA & NEW ZEALAND ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 41: INDIA ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 42: SOUTH KOREA ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 43: THAILAND ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 44: INDONESIA ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 45: VIETNAM ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 46: REST OF ASIA PACIFIC ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 47: REST OF WORLD ANTICOAGULANTS MARKET, REGIONAL OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 48: LATIN AMERICA ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 49: MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)